ArticleTherapeutic advances in gastroenterology2019
Susceptibility-guided therapy for
Article in Therapeutic advances in gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03413020 (Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Eradication efficacy of empiric bismuth quadruple therapy containing amoxicillin in the first-line treatment of Helicobacter pylori in Ningxia, China.BMC gastroenterology · 2026Article
- Review
- Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment ofFrontiers in medicine · 2024Article
- Clinical evaluation of a real-time PCR assay for diagnosis ofInternational journal of clinical and experimental pathology · 2024Article
- Review
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.Clinical microbiology reviews · 2022Review
- Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Review
- Treatment of RefractoryGut and liver · 2022Review
- Empirical vs. Susceptibility-Guided Treatment ofFrontiers in microbiology · 2022Article
- Treatment of refractoryFrontiers in microbiology · 2022Review
- High-dose dual therapyTherapeutic advances in gastroenterology · 2022Article
- Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies.Gastroenterology · 2021Article
- Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides.Nature communications · 2021Article
- Recent progress in Helicobacter pylori treatment.Chinese medical journal · 2020Review
- Efficacy of tailored second-line therapy ofGut pathogens · 2020Article
- Culture-based antibiotic susceptibility testing forAnnals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmpirical therapy of
methodsThis was a prospective study of consecutive 200 patients infected with
resultsThe eradication rate of susceptibility-guided therapy overall was 94.5% (189/200, 95% confidence interval: 90.4-97.2%). Around 28% (56/200) of patients carried strains susceptible to one of the tested antibiotics and were prescribed the triple therapy. A total of 144 multidrug-resistant patients received bismuth quadruple therapy. The eradication rates were all greater than 90%, i.e. 91.7% (11/12), 92.3% (12/13), and 93.5% (29/31) in those who received clarithromycin, metronidazole, and levofloxacin-containing triple therapy and 95.1% (137/144) for the bismuth quadruple therapy. There were no differences in eradication rates between the subgroups.
conclusionsAlthough susceptibility-guided therapy proved high efficacious despite the high proportion of multidrug-resistant strains, the strategy suggested the best approach for this population would be empirical amoxicillin-containing bismuth quadruple therapy. ClinicalTrials.gov identifier: NCT03413020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.